A groundbreaking drug delivery method called GlycoCaging could revolutionize treatment for inflammatory bowel disease (IBD) by targeting the gut with significantly lower drug doses. Published in Science, this proof-of-concept study, led by researchers at the University of British Columbia (UBC), uses molecules derived from fruit and vegetable fiber to release medication exclusively in the lower gut, reducing side effects associated with current therapies.
The study addresses a critical challenge in IBD treatment: much of the medicine taken orally or intravenously is absorbed before reaching the inflamed gut, requiring high doses that cause severe side effects like osteoporosis and diabetes. GlycoCaging binds drugs to molecules digestible only by gut bacteria, creating a targeted “treasure chest” system.
In tests on mice with IBD, GlycoCaged steroids achieved anti-inflammatory effects at doses 3 to 10 times lower than standard treatments, with minimal systemic exposure. The team also confirmed that the necessary bacteria are present in human gut microbiomes, including in IBD patients, suggesting broad applicability.
“This technique can deliver steroids, antimicrobials, and other drugs directly to the gut, potentially helping millions worldwide,” said Dr. Harry Brumer, co-senior author and UBC professor. Dr. Laura Sly added, “IBD strikes young adults in their prime, and GlycoCaging offers hope for safer, more effective therapy.”
With over 322,600 Canadians affected by IBD, one of the highest global rates, this innovation could transform care by minimizing side effects and repurposing potent drugs. Future research will explore clinical applications in humans.
Add comment